Cybrexa Therapeutics has appointed pharmaceutical and financial services veteran Stephen Basso as Chief Financial Officer.
“With our lead therapeutic candidate, CBX-12, currently in its Phase 1 trial, it is important that we continue charting this candidate’s development path,” said Per Hellsund, President and CEO of Cybrexa. “With decades of experience in strategic financial planning and analysis in the pharmaceutical industry, Stephen is both a proven talent and a timely addition to Cybrexa. We look forward to the doors that his financial and pharmaceutical expertise will no doubt unlock for the company, as we continue toward providing cancer patients with more treatment options.”